The State of Patient-Reported Outcomes in Atrial Fibrillation
- 1 January 2005
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 23 (7) , 687-708
- https://doi.org/10.2165/00019053-200523070-00004
Abstract
Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting approximately 2.2 million people in the US. The presentation of AF ranges from asymptomatic to severely symptomatic. When symptomatic, AF has been shown to have an adverse impact on health-related quality of life (HR-QOL) and to result in increased healthcare costs. The objective of this analysis was to review the current AF literature on patient-reported outcomes (PROs) in order to evaluate the impact of AF on PROs and the applicability of current PRO measures in assessing AF outcomes. HR-QOL and symptoms were the most frequently assessed PROs; however, the sensitivity of the majority of the questionnaires for detecting subtle change is not known. For highly symptomatic patients, interventional procedures reduce symptoms and improve HR-QOL; however, this is a small cohort of patients with AF. For the most part, PROs are equivalent between pharmacological treatments or are not known for the large percentage of patients treated pharmacologically with antiarrhythmic or rate-controlling drugs. PRO assessment in AF patients is an area that needs continued development. AF-specific PRO measures are needed to assess the full range of patient symptoms and treatment outcomes. The impact of paroxysmal AF versus permanent AF is not well delineated, and sex and nationality differences are not known. In addition, the impact of AF on daily activities and HR-QOL is not clearly described.Keywords
This publication has 71 references indexed in Scilit:
- Incorporating the Patient's Perspective into Drug Development and Communication: An Ad Hoc Task Force Report of the Patient-Reported Outcomes (PRO) Harmonization Group Meeting at the Food and Drug Administration, February 16, 2001Value in Health, 2003
- Effect of an implantable cardioverter defibrillator with atrial detection and shock therapies on patient-perceived, health-related quality of lifeAmerican Heart Journal, 2003
- Electrical cardioversion for atrial fibrillation: outcomes in ‘real-life’ clinical practiceInternational Journal of Cardiology, 2001
- Comparison of Quality of Well-Being scale and NYHA functional status classification in patients with atrial fibrillationAmerican Heart Journal, 1998
- Impact on ventricular function and quality of life of transcatheter ablation of the atrioventricular junction in chronic atrial fibrillation with a normal ventricular responseThe American Journal of Cardiology, 1996
- Cardiovascular risk factors, ECG abnormalities and quality of life in subjects with atrial fibrillationInternational Journal of Public Health, 1996
- Quality of life and outcomes after radiofrequency His-bundle catheter ablation and permanent pacemaker implantation: Impact of treatment in paroxysmal and established atrial fibrillationAmerican Heart Journal, 1996
- Long‐Term Follow‐Up of Patients Treated By Radiofrequency Ablation of the Atrioventricular JunctionPacing and Clinical Electrophysiology, 1995
- Influence of atrioventricular junction radiofrequency ablation in patients with chronic atrial fibrillation and flutter on quality of life and cardiac performanceThe American Journal of Cardiology, 1994
- Correlation of symptoms with occurrence of paroxysmal supraventricular tachycardia or atrial fibrillation: A transtelephonic monitoring studyAmerican Heart Journal, 1992